Not Signed In - HIV - Schering-Plough Provides Update On Phase II Study Of Vicriviroc
Sun, 05 Mar 2006 11:00 PM EST
... Schering-Plough Corporation (NYSE: SGP) today provided an update on vicriviroc, its investigational CCR5 receptor antagonist, currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing Phase II clinical study of 118 U.S. treatment-experienced HIV patients. Patients who entered this trial were heavily treatment experienced with advanced HIV disease and low CD4 counts... click link for more info. ...
Related Topics
- HIV/AIDS & STDs
- HIV Testing
- HIV Antibody
- Pets and Pet Health
- Clinical Trials
- Nystatin and Triamcinolone
- Perinatal HIV
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Acquired Immune Deficiency Syndrome
- Healthcare Workers
- HIV/AIDS Surveillance Reports
- Kniest dysplasia
- Radiation Studies
- Hiv / Human Immunodeficiency Virus
- Chloroquine
- CD4
- Juvenile Diabetes
- Phenylephrine and Guaifenesin Capsules
- Polio Vaccine & Origin of HIV/AIDS
email this page
print this page
bookmark this page
feedback on this page
